Studying eye fluid to improve treatment for wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years of age or older.
- You must have a confirmed diagnosis of 'wet' age-related macular degeneration (AMD) in one eye, causing symptoms like blurred or distorted central vision.
- You must either have never received treatment for wet AMD in that eye, or have had exactly 3 monthly injections of ranibizumab (Lucentis) as your only previous treatment.
- Your vision in the affected eye must be between 20/32 and 20/320 on a standard eye chart (meaning you can read some letters but not others).
- You must not have other eye conditions (like diabetic eye disease, severe nearsightedness, prior eye surgery, or uncontrolled glaucoma) that could affect the study.
- You must be willing to undergo study procedures, including an eye exam, imaging, and a sample of your eye's fluid (vitreous humor) during an injection procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.